Johnson & Johnson Reports Positive CARTITUDE-4 Results for Carvykti CAR-T in Multiple Myeloma

Johnson & Johnson today announced positive results from the Phase 3 CARTITUDE-4 trial evaluating Carvykti (ciltacabtagene autoleucel) versus standard of care in patients with relapsed or refractory multiple myeloma who had received one to three prior lines of therapy. The risk of disease progression or death was reduced by 74% compared to standard of care.